ABN AMRO
Progress on ABN AMRO share buyback programme 7 August - 14 August 2025
Progress on ABN AMRO share buyback programme 7 August - 14 August 2025
Progress on ABN AMRO share buyback programme 7 August - 14 August 2025
ABN AMRO reports the transaction details related to its EUR 250 million share buyback programme announced on 6 August 2025.
During the week of 7 August 2025 up to and including 14 August 2025 a total of 2,400,000 shares and depositary receipts were repurchased at an average price of €25.72 for a total amount of € 61,717,760.
For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme.
To date the total consideration for shares and depositary receipts repurchased amounts to € 61,717,760 representing 24.69% of the overall share buyback programme.
This press release is published by ABN AMRO Bank N.V. and contains inside information within the meaning of article 7 (1) to (4) of Regulation (EU) No 596/2014 (Market Abuse Regulation).
Note to editors, not for publication.
For more information, please contact
ABN AMRO Press Office: e-mail: pressrelations@nl.abnamro.com, phone number: +31 (0)20 6288900
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S31.8.2025 09:09:18 CEST | Press release
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Novartis Pharma AG30.8.2025 17:00:00 CEST | Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
F. Hoffmann-La Roche Ltd30.8.2025 16:30:00 CEST | Press release
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
CGTN30.8.2025 11:44:44 CEST | Pressemeddelelse
CGTN: Arven efter Flying Tigers fejres for at styrke det varige bånd mellem Kina og USA
Sanofi Winthrop Industrie29.8.2025 23:50:03 CEST | Press release
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom